Atherotech Unveils New Cardiometabolic Test Panels

Heart disease and diabetes markers to complement VAP advanced cholesterol
profile

ORLANDO, Fla. and BIRMINGHAM, Ala., March 30 /PRNewswire/ -- Atherotech, Inc.,
developer of the VAP Cholesterol Test, has announced the addition of new
cardiovascular and metabolic testing panels at ACC.09, the American College of
Cardiology (ACC) 58th Annual Scientific Session Exposition. Atherotech is
adding more than a dozen new tests, including C-Reactive Protein (hsCRP), ApoE
genotype, and NT-proBNP, for assessment of patients at intermediate to high
risk of cardiometabolic diseases. The company is also adding advanced and
follow-up cardiovascular disease (CVD) risk profiles.

"We're maximizing the value of our core VAP technology with additional
cardiometabolic tests," said Atherotech President Michael Mullen. "This
provides physicians and cardiology practices with a single source for the VAP
Cholesterol Test plus the new test panels. You get the complete cardiovascular
and metabolic view."

Atherotech representatives will be available to discuss the VAP Cholesterol
Test and new test panels in booth #1263, and blood draws will be provided to
qualified attendees during exhibit hours March 29-31. Because LDL is directly
measured, fasting is not required. Test results will be returned via mail
after the conference.

The VAP Test, which recently added apoAI (and the apoB/apoAI ratio) to its
panel, uses advanced lipid profile testing in the identification of
individuals at increased risk of heart disease. The new test panels enable
Atherotech to increase its scientific and diagnostic capabilities by offering
much more complete cardiometabolic testing.

Steven Margolis, M.D., FAAFP, DABCL, a board-certified lipidologist who
currently uses the VAP Test for advanced lipid testing of patients in his
Sterling Heights, Mich., practice, says the new testing panels add significant
benefits for practices such as his.

"It's very convenient for physicians to be able to get these heart disease
risk factor tests grouped together and not have to deal with multiple
reference labs," said Margolis. "They're also now offering specialized tests
such as apoE genetic testing and NT-proBNP that aren't offered by most other
reference laboratories."

The new test panels are available immediately and also include homocysteine,
creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN),
glucose, vitamin D, fibrinogen and insulin. The tests can be ordered
individually, or bundled as part of a custom risk profile that may also
include the VAP Test.

The VAP Test provides researchers and medical professionals with direct
measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a
highly accurate determination of apoB, and emerging risk factors such as
Lp(a), remnants and small dense LDL. The VAP (Vertical Auto Profile) Test is
now the only single cholesterol test that routinely reports apoAI, apoB, and
the apoB/apoAI ratio.

For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests,
including the company's patented VAP Cholesterol Test, which reports the
cholesterol content of all lipids, components and subclasses. The VAP Test is
the first cholesterol profile to comply with updated National Cholesterol
Education Program ATP III recommendations for direct LDL measurement, which is
accurate with non-fasting samples. It is the only advanced lipid profile that
routinely reports all three lipoprotein parameters considered necessary by the
American Diabetes Association and American College of Cardiology expert
consensus guidelines. The VAP Test is available through national and regional
diagnostic laboratories and is reimbursed by many of the largest private
insurers as well as Medicare. For more information, visit www.thevaptest.com.

SOURCE Atherotech, Inc.

Dan Snyders of Armada Medical Marketing, +1-303-623-1190 x230,
dan@armadamedical.com, for Atherotech, Inc.; or Scott Rezek of Atherotech,
Inc., +1-205-314-7412, srezek@atherotech.com